11099 Torrey Pines Park Road
About Fortis Therapeutics
Fortis Therapeutics is an immuno-oncology biotech focused on developing new antibody drug conjugate therapies for late-stage multiple myeloma and late-stage prostate cancer. Fortis was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D. The company's investors are Avalon Ventures, Bregua Corporation, Lilly Asia Ventures, Osage University Partners, and Vivo Capital. Fortis Therapeutics is located in COI Pharmaceuticals, Avalon's Community of Innovation, in San Diego.
President and CEO: Jay Lichter, Ph.D
CSO: Marc Nasoff, Ph.D.
CFO: Tighe Reardon
Principal Scientist: Joshua Park, Ph.D.
5 articles with Fortis Therapeutics
Thought-leading industry veteran brings two decades of life sciences and biotechnology experience to the company's Board of Directors
Fortis Therapeutics Receives FDA Clearance of Two IND Applications for Novel Anti-CD46 Therapeutic for Treatment of Late-Stage Prostate Cancer and Multiple Myeloma
The Phase 1 trial of FOR46 in metastatic castration-resistant prostate cancer is planned to launch by the end of the year.
Fortis Therapeutics is focused on immuno-oncology, specifically on developing an ADC for multiple myeloma and late-stage prostate cancer, including both the adenocarcinoma and neuroendocrine types.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.